Bruce A W, Mahan D E, Sullivan L D, Goldenberg L
J Urol. 1981 Mar;125(3):357-60. doi: 10.1016/s0022-5347(17)55036-3.
Our radioimmunoassay for prostatic acid phosphatase was compared to commercial radioimmunoassay kits. A close correlation among all 3 assays was found in control groups, and in patients with benign prostatic hyperplasia and adenocarcinoma of the prostate. These results also were compared to recent reports from other centers using similar methodologies. In 7 to 15 per cent of the patients with bone metastasis normal levels of serum prostatic acid phosphatase were found. Variability in prostatic acid phosphatase production by the tumor may account for this finding. Elevated levels of prostatic acid phosphatase were associated more commonly with less differentiated primary tumors. A low percentage of prostatic acid phosphatase elevations in patients with early localized and incidental adenocarcinoma was found for the 3 assays evaluated. These factors, along with the falsely positive rates in patients with benign disease, limit severely the application of these assays to the screening of male patients at risk for adenocarcinoma of the prostate.
我们对前列腺酸性磷酸酶的放射免疫测定法与商用放射免疫测定试剂盒进行了比较。在对照组、良性前列腺增生患者和前列腺腺癌患者中，发现所有这三种测定方法之间具有密切相关性。这些结果还与其他中心近期使用类似方法的报告进行了比较。在7%至15%的骨转移患者中，发现血清前列腺酸性磷酸酶水平正常。肿瘤产生前列腺酸性磷酸酶的变异性可能是这一发现的原因。前列腺酸性磷酸酶水平升高更常见于分化程度较低的原发性肿瘤。在所评估的三种测定方法中，早期局限性和偶发性腺癌患者中前列腺酸性磷酸酶升高的比例较低。这些因素，连同良性疾病患者的假阳性率，严重限制了这些测定方法在筛查有前列腺腺癌风险的男性患者中的应用。
